Lin LY, et al. - During the 2016–2019 International Network for Optimal Resistance Monitoring program, evaluation of antibacterial activity of ceftazidime-avibactam (CAZ-AVI) against bacterial isolates from children in the United States with a urinary tract infection (UTI) or intra-abdominal infection (IAI) was performed. Researchers here compared the prevalence of isolates and susceptibility to CAZ-AVI in pediatric and adult patients. Collection of bacterial isolates was done from children with a UTI or IAI at 70 US medical centers from 2016 to 2019. In children with UTIs, Escherichia coli (62.5%), Klebsiella pneumoniae (12.1%) and Proteus mirabilis (6.2%) were the most prevalent Enterobacterales pathogens. In children with IAIs, E. coli (57.4%), K. pneumoniae (11.1%) and Enterobacter cloacae species complex (9.3%) were the most prevalent Enterobacterales pathogens. Per findings, contemporary UTI and IAI pathogens collected from US children from 2016 to 2019 had prevalence and susceptibilities similar to that of isolates obtained from adult patients. Potent activity was exhibited by CAZ-AVI against these pathogens.